Download Antitargets: Prediction and Prevention of Drug Side Effects by Roy J. Vaz, Thomas Klabunde, Raimund Mannhold, Hugo Kubinyi, PDF

By Roy J. Vaz, Thomas Klabunde, Raimund Mannhold, Hugo Kubinyi, Gerd Folkers

This practice-oriented guide surveys present wisdom at the prediction and prevention of difficult drug reactions concerning off-target task of small molecule medications. it really is detailed in collating the present techniques right into a unmarried resource, and comprises numerous hugely instructive case reviews that could be used as instructions on tips on how to enhance drug improvement initiatives. With its huge part on ADME-related results, this can be key wisdom for each drug developer.

Show description

Read Online or Download Antitargets: Prediction and Prevention of Drug Side Effects PDF

Similar industrial & technical books

Multivariate Datenanalyse GERMAN

In vielen Fachgebieten, wie z. B. der Lebensmittelchemie, der pharmazeutischen oder biotechnologischen Industrie fallen immer mehr Daten an, die ausgewertet werden m? ssen. Klassische Verfahren gelangen hierbei schnell an ihre Grenzen. Die multivariate Datenanalyse besch? ftigt sich mit Verfahren, mit denen guy aus einer F?

Enzymes in Biomass Conversion

Content material: Enzymes for fuels and chemical feedstocks / ok. Grohmann and Michael E. Himmel -- Enzymes in pulp and paper processing / L. Viikari, A. Kantelinen, M. Rättö, and J. Sundquist -- Enzymes for anaerobic municipal good waste disposal / Christopher J. Rivard, William S. Adney, and Michael E. Himmel -- Thermostable saccharidases : new assets, makes use of, and biodesigns / J.

Extra resources for Antitargets: Prediction and Prevention of Drug Side Effects

Example text

S. (2004) Molecular biology: NIH molecular libraries initiative (Policy forum). Science, 306, 1138–1139. , Ferrara, G. L. (2006) Screening the receptorome: an efficient approach for drug discovery and target validation. Drug Discovery Today, 11, 708–716. V. (2004), Thalidomide: tragic past and promising future. Mayo Clinic Proceedings, 79, 899–903. R. D. (2004) Thalidomide. The Lancet, 363, 1802–1811. I. B. (2005) Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discovery Today, 10, 107–114.

And Shatin, D. (2003) Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. The American Journal of Gastroenterology, 98, 175–179. (2004) AstraZeneca first launch for AstraZeneca's Exanta (TM) (ximelagatran): the first oral anticoagulant in new class of direct thrombin inhibitors (DTIs), AstraZeneca. (2006) AstraZeneca. AstraZeneca decides to withdraw Exanta (TM), AstraZeneca. DuBose, R. (2002) Lotronex tablets to be re-introduced for women with severe diarrhea-predominant IBS, GSK.

Roche Fachinformation (Zusammenfassung der Produkteigenschaften) POSICOR, “Roche” 50 mg-Filmtabletten, 1998. Ross, D. Telithromycin (Ketek): General Safety Profile. htm, last accessed on 17th March 2003. Berthold, H. (1998) Rückruf von Cerate (Mibefradil) angeordnet; Arzneimittelkommission der Deutschen Ärzteschaftf. G. (2001) Rapacuronium and bronchospasm. Anesthesiology, 94, 727–728. M. and FuchsBuder, T. (2001) Newer neuromuscular blocking agents: how do they compare with establishes agents? Drugs, 61, 919–942.

Download PDF sample

Rated 4.15 of 5 – based on 29 votes